High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries.

Stephen Yanofsky(Affymax (United States)), D. N. Baldwin(Affymax (United States)), John H. Butler(Affymax (United States)), Frank Holden(Affymax (United States)), Jeffrey Jacobs(Affymax (United States)), P Balasubramanian(Affymax (United States)), Jason Chinn(Affymax (United States)), Steven E. Cwirla(Affymax (United States)), E Peters-Bhatt(Affymax (United States)), Erik A. Whitehorn(Affymax (United States)), Emily Tate(Affymax (United States)), Åke Åkeson(Affymax (United States)), Terry L. Bowlin(Affymax (United States)), William J. Dower(Affymax (United States)), Ronald W. Barrett(Affymax (United States))
Proceedings of the National Academy of Sciences
July 9, 1996
Cited by 111Open Access

Abstract

Two families of peptides that specifically bind the extracellular domain of the human type I interleukin I (IL-1) receptor were identified from recombinant peptide display libraries. Peptides from one of these families blocked binding of IL-lalpha to the type I IL-1 receptor with IC50 values of 45-140 microM. Affinity-selective screening of variants of these peptides produced ligands of much higher affinity (IC50 approximately 2 nM). These peptides block IL-1-driven responses in human and monkey cells; they do not bind the human type II IL-1 receptor or the murine type I IL-1 receptor. This is the first example (that we know of) of a high affinity peptide that binds to a cytokine receptor and acts as a cytokine antagonist.


Related Papers

No related papers found

Powered by citation graph analysis